secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001193125-24-135478
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno Q1 net loss $21.4M; FDA breakthrough therapy for DCCR; NDA mid-2024
--------------------------------------------------------------------------

- Net loss of $21.4M ($0.59 per share) vs $8.4M loss in Q1 2023; R&D expense rose to $14.6M from $5.3M.
- Pro forma cash reserves $307.2M after May 2024 public offering netting $148.8M.
- FDA granted Breakthrough Therapy Designation for DCCR in Prader-Willi syndrome; NDA submission on track for mid-2024.
- Strengthened leadership: appointed Chief Commercial Officer, VP Europe, VP Human Resources.
- Contingent consideration liability for DCCR commercial milestones valued at $12.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312524135478/0001193125-24-135478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312524135478/d767565d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-135478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer